


listen to their heart

Reduce CV risk
together now

- ✓ POWERFUL* .1-4
- ✓ RAPID** .1,5
- ✓ PREVENTIVE*** .6

**Initiate Repatha®
for Your Next
High-Risk Patient!**



CV: cardiovascular
* Significant reduction in LDL-C by approximately to 75 %¹⁻⁴
** LDL-C reduction starting as early as week 1,5
*** Repatha® reduces CV risk by 25 % in patients after acute MI⁶
x Repatha® reduced the relative risk of further cardiovascular events (CV death, MI, or stroke) in patients who had suffered a myocardial infarction within the previous 12 months by 19 % in the primary endpoint and by 25 % in the secondary primary endpoint (Gencer B, et al. 2020).

REFERENCES:
1. Current summary of product characteristics Repatha®.
2. Sabatine MS, et al. N Engl J Med. 2017; 376(18):1713-1722.
3. Robinson JG, et al. JAMA. 2014; 311:1870-1882.
4. Koren JM, et al. J Am Coll Cardiol. 2019; 74(17):2132-2146.
5. Kaschayanula S, et al. Clin Pharmacokinet. 2018; 57:769-779.
6. Gencer B, et al. JAMA Cardiol. 2020; 5(8):3-6.

KWT 145-26-80068

The people shown were generated using artificial intelligence.

API available upon request.

AMGEN®

Business Central Tower A,
Office 2007,
20th floor Dubai Media City
PO Box 502607
Dubai, UAE